These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 6117922

  • 61.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 62. Clinical use of the radioreceptor assay for neuroleptics.
    Cohen BM, Lipinski JF, Harris PQ, Pope HG, Friedman M.
    Psychiatry Res; 1980 May; 2(2):173-8. PubMed ID: 6106254
    [Abstract] [Full Text] [Related]

  • 63. Depot neuroleptics: side effects and safety.
    Marder SR.
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):24S-29S. PubMed ID: 2870089
    [Abstract] [Full Text] [Related]

  • 64. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment.
    Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B.
    Am J Psychiatry; 2001 Jun; 158(6):918-25. PubMed ID: 11384900
    [Abstract] [Full Text] [Related]

  • 65. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects.
    Kinon BJ, Kane JM, Chakos M, Munne R.
    Psychopharmacol Bull; 1993 Jun; 29(3):365-9. PubMed ID: 7907184
    [Abstract] [Full Text] [Related]

  • 66.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 67. Acute extrapyramidal syndromes in neuroleptic-treated elders: a pilot study.
    Ganzini L, Heintz R, Hoffman WF, Keepers GA, Casey DE.
    J Geriatr Psychiatry Neurol; 1991 Jun; 4(4):222-5. PubMed ID: 1686396
    [Abstract] [Full Text] [Related]

  • 68. Clinical experience in developing treatment regimens with the novel antipsychotic risperidone.
    Kopala LC.
    Int Clin Psychopharmacol; 1997 Sep; 12 Suppl 4():S11-8. PubMed ID: 9352341
    [Abstract] [Full Text] [Related]

  • 69. Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics.
    Prosser ES, Csernansky JG, Kaplan J, Thiemann S, Becker TJ, Hollister LE.
    J Nerv Ment Dis; 1987 Feb; 175(2):100-5. PubMed ID: 2879880
    [Abstract] [Full Text] [Related]

  • 70. A radioreceptor assay for neuroleptic drugs in plasma.
    Lader SR.
    J Immunoassay; 1980 Feb; 1(1):57-75. PubMed ID: 6112242
    [Abstract] [Full Text] [Related]

  • 71. Antipsychotic medication: clinical guidelines for maintenance therapy.
    Johnson DA.
    J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
    [Abstract] [Full Text] [Related]

  • 72. Recognition and management of acute neuroleptic-induced extrapyramidal motor and mental syndromes.
    Dose M.
    Pharmacopsychiatry; 2000 Sep; 33 Suppl 1():3-13. PubMed ID: 11072761
    [Abstract] [Full Text] [Related]

  • 73. Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders.
    Lafuente A, Bernardo M, Mas S, Crescenti A, Aparici M, Gasso P, Deulofeu R, Mane A, Catalan R, Carne X.
    Psychiatry Res; 2008 Nov 30; 161(2):131-41. PubMed ID: 18922583
    [Abstract] [Full Text] [Related]

  • 74. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes.
    Keepers GA, Clappison VJ, Casey DE.
    Arch Gen Psychiatry; 1983 Oct 30; 40(10):1113-7. PubMed ID: 6138011
    [Abstract] [Full Text] [Related]

  • 75. Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone.
    Tracy JI, Monaco CA, Abraham G, Josiassen RC, Pollock BG.
    J Clin Psychiatry; 1998 Apr 30; 59(4):184-8. PubMed ID: 9590669
    [Abstract] [Full Text] [Related]

  • 76. Neuroleptic drug level monitoring in psychiatry: focus on radioreceptor assay techniques.
    Tune LE, Coyle JT.
    Ther Drug Monit; 1982 Apr 30; 4(1):59-64. PubMed ID: 6122293
    [Abstract] [Full Text] [Related]

  • 77. Characterizing anticholinergic abuse in community mental health.
    Wells BG, Marken PA, Rickman LA, Brown CS, Hamann G, Grimmig J.
    J Clin Psychopharmacol; 1989 Dec 30; 9(6):431-5. PubMed ID: 2592590
    [Abstract] [Full Text] [Related]

  • 78. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol.
    Tauscher J, Küfferle B, Asenbaum S, Tauscher-Wisniewski S, Kasper S.
    Psychopharmacology (Berl); 2002 Jun 30; 162(1):42-9. PubMed ID: 12107616
    [Abstract] [Full Text] [Related]

  • 79. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
    Matsui-Sakata A, Ohtani H, Sawada Y.
    Drug Metab Pharmacokinet; 2005 Jun 30; 20(3):187-99. PubMed ID: 15988121
    [Abstract] [Full Text] [Related]

  • 80. The treatment and management of neuroleptic malignant syndrome.
    Gratz SS, Levinson DF, Simpson GM.
    Prog Neuropsychopharmacol Biol Psychiatry; 1992 Jul 30; 16(4):425-43. PubMed ID: 1641490
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.